

### REMARKS

The claims have been amended to conform to applicants' election; embodiments directed to non-elected inventions no longer appear in the claims. Further, amendments have been made to overcome the rejection under 35 U.S.C. § 112, paragraph 2, as further outlined below. More precise definitions of substituents have been inserted based on the description in the specification on pages 10-15.

No new matter has been added and entry of the amendment is respectfully requested.

#### Claim Objection

The objection to claim 1 is mooted by the amendment which deletes the objected-to phrase.

#### The Rejection Under 35 U.S.C. § 112, Second Paragraph

With regard to the rejections under 35 U.S.C. § 112, paragraph 2, these will be taken in turn.

In paragraph a, claim 1 and claims dependent thereon were rejected because assertedly the phrase "non-interfering substituents" is not clear. This is directly addressed by amendment. The non-interfering substituents have been identified in detail. The "non-interfering substituents" that are substituted on Ar<sup>1</sup> are listed as described on pages 11-12, beginning at line 30 on page 11. The L<sup>1</sup> and L<sup>2</sup> linkers have been specified in the formula. R<sup>1</sup> is defined as those substituents listed on pages 12-13, beginning on line 27 of page 12. Ar<sup>2</sup> is specifically defined as set forth on page 6 and the R group attached to the specified rings is defined consistently with the substituents on Ar<sup>1</sup> as set forth on page 11, beginning at line 30. R<sup>3</sup> is specifically defined as set forth on page 13, beginning at line 24. Thus, all of the "non-interfering substituents" have been defined structurally.

With respect to paragraph b, the term “spacer” has been replaced by “an alkylene” which renders this phrase clearly definite.

With respect to paragraph c, the nature of the isosteres has been specified as tetrazole, 1,2,3-triazole; 1,2,4-triazole, or imidazole as set forth in the specification on page 15.

With respect to paragraph d, the objected to phrase has been deleted from the claims and Ar<sup>2</sup> has been defined in terms of structure.

The rejection in paragraph e applied to claim 5 is mooted by cancellation of this claim.

Similarly, the objection in paragraph f with regard to claim 8 is mooted by its cancellation.

Applicants believe that the foregoing amendment and remarks dispose of all the outstanding bases for rejection. In view of this, applicants respectfully request that the pending claims, claims 1, 6, 10, 16-21, 23-26, 28-30, 43-45, 47-49, 51 and 53 be passed to issue.

Claims 55-56 have been canceled as directed to a non-elected invention; however, it is believed that claims 57, 59 and 60, which were withdrawn from consideration, may properly be rejoined as they are methods of use dependent on an allowable composition claim.


Conclusion

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. 219002029210.

Respectfully submitted,

Dated: February 23, 2006

By:



Kate H. Murashige

Registration No. 29,959

MORRISON & FOERSTER LLP

12531 High Bluff Drive, Suite 100

San Diego, California 92130-2040

Telephone: (858) 720-5112

Facsimile: (858) 720-5125